PMID- 17387741
OWN - NLM
STAT- MEDLINE
DCOM- 20070626
LR  - 20221207
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 109
IP  - 9
DP  - 2007 May 1
TI  - Comparative analysis of epidermal growth factor receptor mutations and gene 
      amplification as predictors of gefitinib efficacy in Japanese patients with 
      nonsmall cell lung cancer.
PG  - 1836-44
AB  - BACKGROUND: Because the investigation of epidermal growth factor receptor gene 
      (EGFR) status as a predictor of gefitinib efficacy in Japanese patients has shown 
      promise, the authors evaluated EGFR mutations and gene amplification in biopsy 
      specimens from Japanese patients with nonsmall cell lung cancer (NSCLC) who 
      received treatment with gefitinib to analyze the correlation between EGFR gene 
      status and clinical outcome. METHODS: Fifty-nine patients were enrolled in this 
      study. EGFR gene amplification was evaluated by fluorescence in situ 
      hybridization (FISH), and EGFR mutations in exons 18, 19, and 21 were analyzed by 
      polymerase chain reaction and direct sequencing. RESULTS: EGFR mutations were 
      detected in 17 patients (28.8%). FISH-positive results were observed in 26 
      patients (48.1%). The response rate was significantly higher in the patients with 
      EGFR mutations than in the patients without mutations (58.8% vs 14.3%; P=.0005). 
      No significant difference in the response rate was observed between FISH-positive 
      patients and FISH-negative patients (31.8% vs 21.4%; P=.4339). EGFR mutation was 
      correlated with both a longer time to progression (TTP) (7.3 months vs 1.8 
      months; P=.0030) and longer overall survival (OS) (18.9 months vs 6.4 months; 
      P=.0092). No significant differences in TTP or OS were observed between 
      FISH-positive patients andFISH-negative patients. The results from a multivariate 
      analysis indicated that EGFR mutations maintained a significant association with 
      longer TTP and longer OS. CONCLUSIONS: The results of this study suggested that 
      EGFR mutations may serve as predictors of response and survival and that the role 
      of EGFR gene amplification is not a predictor of gefitinib efficacy in Japanese 
      patients with NSCLC.
CI  - Copyright (c) 2007 American Cancer Society
FAU - Sone, Takashi
AU  - Sone T
AD  - Respiratory Medicine, School of Medicine, Kanazawa University, Kanazawa, and 
      Shien-Lab, National Cancer Center Hospital, Tokyo, Japan.
FAU - Kasahara, Kazuo
AU  - Kasahara K
FAU - Kimura, Hideharu
AU  - Kimura H
FAU - Nishio, Kazuto
AU  - Nishio K
FAU - Mizuguchi, Masayuki
AU  - Mizuguchi M
FAU - Nakatsumi, Yasuto
AU  - Nakatsumi Y
FAU - Shibata, Kazuhiko
AU  - Shibata K
FAU - Waseda, Yuko
AU  - Waseda Y
FAU - Fujimura, Masaki
AU  - Fujimura M
FAU - Nakao, Shinji
AU  - Nakao S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Quinazolines)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Asian People
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/*genetics/mortality
MH  - ErbB Receptors/*genetics
MH  - Female
MH  - Gefitinib
MH  - Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/drug therapy/*genetics/mortality
MH  - Male
MH  - Mutation
MH  - Quinazolines/*therapeutic use
MH  - Retrospective Studies
EDAT- 2007/03/28 09:00
MHDA- 2007/06/27 09:00
CRDT- 2007/03/28 09:00
PHST- 2007/03/28 09:00 [pubmed]
PHST- 2007/06/27 09:00 [medline]
PHST- 2007/03/28 09:00 [entrez]
AID - 10.1002/cncr.22593 [doi]
PST - ppublish
SO  - Cancer. 2007 May 1;109(9):1836-44. doi: 10.1002/cncr.22593.